Gene therapy shot aims to ease diabetic foot pain
NCT ID NCT01475786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a gene therapy called Engensis (VM202) to see if it safely reduces pain in people with diabetic peripheral neuropathy. 104 adults with type 1 or 2 diabetes and leg pain for at least 6 months received either low-dose, high-dose, or placebo injections into their calves. The main goal was to measure changes in average daily pain over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Engensis (VM202) gene therapy
What this could lead to
If it works, this could offer a new way to reduce chronic pain in people with diabetic nerve damage.
What could go wrong
This is an early phase 2 trial with only 104 people, so results may not apply to everyone. The treatment involves injections into the calves and may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAINFUL DIABETIC NEUROPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess
Boston, Massachusetts, 02115, United States
-
Compass Research
Orlando, Florida, 32806, United States
-
Diablo Clinical Research
Walnut Creek, California, 94598, United States
-
East Virginia Medical School Strelitz Diabetes Center
Norfolk, Virginia, 23510, United States
-
Houston Neurocare
Houston, Texas, 77030, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Palm Beach Neurological Center
Palm Beach Gardens, Florida, 33418, United States
-
Rainier Clinical Research
Seattle, Washington, 98057, United States
-
Sejong General Hospital
Bucheon-si, Sosa-gu, 422-711, South Korea
-
Seoul National University Bundang Hospital
Seongnam, Bundang-gu, 463-707, South Korea
-
The Catholic University of Korea Youido St. Mary's Hospital
Seoul, Yeongdeungpo-gu, 150-713, South Korea
-
The Methodist Hospital
Houston, Texas, 77030, United States
-
The Neurosciences Institute Albany Medical College
Albany, New York, 12208, United States
-
University of Oklahoma Harold Hamm Diabetes Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
Yonsei University College of Medicine Severance Hospital
Seoul, Seodaemun-gu, 120-752, South Korea